应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09688 再鼎医药
未开盘 11-21 16:08:22
20.500
-0.250
-1.20%
最高
20.650
最低
20.100
成交量
443.62万
今开
20.300
昨收
20.750
日振幅
2.65%
总市值
222.63亿
流通市值
222.63亿
总股本
10.86亿
成交额
9,048万
换手率
0.41%
流通股本
10.86亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
再鼎医药下跌2.19%,报25.655美元/股
金融界 · 11-21 23:29
再鼎医药下跌2.19%,报25.655美元/股
再鼎医药与辉瑞就新型抗菌药物鼎优乐® (舒巴坦钠-度洛巴坦钠)达成战略合作
美通社 · 11-21 19:28
再鼎医药与辉瑞就新型抗菌药物鼎优乐® (舒巴坦钠-度洛巴坦钠)达成战略合作
再鼎医药11月21日主力资金流入1883万元 连续7日加仓
市场透视 · 11-21 16:15
再鼎医药11月21日主力资金流入1883万元 连续7日加仓
再鼎医药11月19日获南向资金加仓277.34万股
市场透视 · 11-20 09:30
再鼎医药11月19日获南向资金加仓277.34万股
再鼎医药根据包销协议发行1176.47万股
新浪港股 · 11-20 09:07
再鼎医药根据包销协议发行1176.47万股
再鼎医药(09688)根据包销协议发行1176.47万股
智通财经 · 11-20 08:25
再鼎医药(09688)根据包销协议发行1176.47万股
再鼎医药上涨5.16%,报26.47美元/股
金融界 · 11-19 23:51
再鼎医药上涨5.16%,报26.47美元/股
再鼎医药(ZLAB)盘前涨超2% 获威灵顿投资管理增持1,012.5万股H股股份 价值约2.82亿美元
金吾财讯 · 11-19 21:42
再鼎医药(ZLAB)盘前涨超2% 获威灵顿投资管理增持1,012.5万股H股股份 价值约2.82亿美元
再鼎医药(09688)授出1.5万份受限制股份单位
智通财经 · 11-19 18:10
再鼎医药(09688)授出1.5万份受限制股份单位
再鼎医药11月19日收跌4.48% 主力资金逆市抢筹
市场透视 · 11-19 16:15
再鼎医药11月19日收跌4.48% 主力资金逆市抢筹
深度 | 再鼎医药融资上瘾,累计亏损超20亿美元
财中社 · 11-19 10:03
深度 | 再鼎医药融资上瘾,累计亏损超20亿美元
异动解读 | 再鼎医药盘中大跌6.7% 新股发行致股权稀释
异动解读 · 11-19 09:39
异动解读 | 再鼎医药盘中大跌6.7% 新股发行致股权稀释
再鼎医药盘中异动 大幅跳水6.13%
市场透视 · 11-19 09:32
再鼎医药盘中异动 大幅跳水6.13%
再鼎医药根据包销协议发行7843.14万股
新浪港股 · 11-19 08:42
再鼎医药根据包销协议发行7843.14万股
再鼎医药(09688)根据包销协议发行7843.14万股
智通财经网 · 11-19 08:05
再鼎医药(09688)根据包销协议发行7843.14万股
再鼎医药盘中异动 股价大涨8.44%
市场透视 · 11-15
再鼎医药盘中异动 股价大涨8.44%
摩根大通增持再鼎医药(09688)118.31万股 每股作价约24.56港元
智通财经网 · 11-15
摩根大通增持再鼎医药(09688)118.31万股 每股作价约24.56港元
再鼎医药盘前涨2.4% 配售美国存托股份 净筹不超2.16亿美元
市场资讯 · 11-15
再鼎医药盘前涨2.4% 配售美国存托股份 净筹不超2.16亿美元
再鼎医药(09688.HK)折让逾4%配售美国存托股份 净筹最多2.16亿美元
阿斯达克财经 · 11-15
再鼎医药(09688.HK)折让逾4%配售美国存托股份 净筹最多2.16亿美元
再鼎医药::第三季度总产品净收入同比增长47%,经营性亏损收窄19%
市场资讯 · 11-15
再鼎医药::第三季度总产品净收入同比增长47%,经营性亏损收窄19%
加载更多
公司概况
公司名称:
再鼎医药
所属市场:
SEHK
上市日期:
--
主营业务:
Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。
发行价格:
--
{"stockData":{"symbol":"09688","market":"HK","secType":"STK","nameCN":"再鼎医药","latestPrice":20.5,"timestamp":1732176502021,"preClose":20.75,"halted":0,"volume":4436225,"delay":0,"floatShares":1086000000,"shares":1086000000,"eps":-2.69483,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.25,"latestTime":"11-21 16:08:22","open":20.3,"high":20.65,"low":20.1,"amount":90482395,"amplitude":0.026506,"askPrice":20.5,"askSize":73900,"bidPrice":20.45,"bidSize":122500,"shortable":3,"etf":0,"ttmEps":-2.1613212025932182,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732239000000},"adr":0,"listingDate":1601222400000,"adjPreClose":20.75,"openAndCloseTimeList":[[1732152600000,1732161600000],[1732165200000,1732176000000]],"volumeRatio":0.6179148670595583,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09688","defaultTab":"news","newsList":[{"id":"2485741539","title":"再鼎医药下跌2.19%,报25.655美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485741539","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485741539?lang=zh_cn&edition=full","pubTime":"2024-11-21 23:29","pubTimestamp":1732202994,"startTime":"0","endTime":"0","summary":"11月21日,再鼎医药(ZLAB)盘中下跌2.19%,截至23:29,报25.655美元/股,成交248.75万美元。财务数据显示,截至2024年09月30日,再鼎医药收入总额2.9亿美元,同比增长44.32%;归母净利润-1.75亿美元,同比增长26.66%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/21232945552896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1574","BK4588","BK4531","BK4548","BK4139","BK4526","BK1588","ZLAB","09688","BK1161","BK4585"],"gpt_icon":0},{"id":"2485935024","title":"再鼎医药与辉瑞就新型抗菌药物鼎优乐® (舒巴坦钠-度洛巴坦钠)达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2485935024","media":"美通社","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485935024?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:28","pubTimestamp":1732188480,"startTime":"0","endTime":"0","summary":"中国上海和美国马萨诸塞州剑桥2024年11月21日 /美通社/ -- 再鼎医药和辉瑞今日宣布,双方就新型抗菌药物鼎优乐达成在中国内地的战略合作,由辉瑞旗下公司独家负责该产品在中国内地的相关商业化运营。新型抗菌药物鼎优乐是目前唯一专门为治疗碳青霉烯类耐药的鲍曼不动杆菌而开发的抗菌药物[1]。再鼎医药在鼎优乐的研发过程中发挥了重要作用,使该药物于今年早些时候在中国获得批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4563341_ZH63341_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["PFE","LU0170899867.USD","LU0225771236.USD","BK4526","LU0456855351.SGD","IE00B19Z3581.USD","BK1161","LU0225284248.USD","ZLAB","BK4533","SG9999001176.USD","IE00B19Z3B42.SGD","BK4581","IE000M9KFDE8.USD","BK4550","BK4139","IE00BLSP4239.USD","09688","LU1066051498.USD","LU0122379950.USD","LU1894683264.USD","LU0289739699.SGD","LU1894683348.USD","LU1057294990.SGD","SG9999013999.USD","BK4585","IE00BLSP4452.SGD","BK1574","BK4592","LU0868494617.USD","LU0234572021.USD","BK4599","LU1023059063.AUD","BK4534","SG9999001176.SGD","BK1588","SGXZ57979304.SGD","LU0058720904.USD","LU1883839398.USD","LU0321505439.SGD","BK4531","LU0321505868.SGD","BK4548","SG9999002232.USD","BK4007","IE00BBT3K403.USD","LU0306807586.USD","SG9999002224.SGD","BK4588","SG9999003800.SGD"],"gpt_icon":1},{"id":"2485455242","title":"再鼎医药11月21日主力资金流入1883万元 连续7日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2485455242","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485455242?lang=zh_cn&edition=full","pubTime":"2024-11-21 16:15","pubTimestamp":1732176946,"startTime":"0","endTime":"0","summary":"11月21日, 再鼎医药股价跌1.20%,报收20.50元,成交金额9048万元,换手率0.41%,振幅2.65%,量比0.62。再鼎医药今日主力资金净流入1883万元,连续7日净流入,上一交易日主力净流入786万元,今日环比增加139.57%。近一年数据显示,该股主力连续7日净流入后,次日上涨概率为14.29%,平均涨幅为0.64%。该股近5个交易日下跌7.21%,主力资金累计净流入1.60亿元;近20日主力资金累计净流入2.18亿元,其中净流入天数为15日。该股主力净额占比0.08%,港股市场排名37/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121161607a24ab5f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121161607a24ab5f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1588","09688"],"gpt_icon":0},{"id":"2484829901","title":"再鼎医药11月19日获南向资金加仓277.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484829901","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484829901?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:30","pubTimestamp":1732066217,"startTime":"0","endTime":"0","summary":"11月19日, 南向资金增持再鼎医药277.34万股。截止当日收盘,港股通共持有再鼎医药9355.77万股,占流通股8.69%。再鼎医药近5个交易日下跌17.18%,港股通累计增持946.56万股;近20个交易日下跌6.03%,港股通累计增持934.71万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120093309a2472385&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120093309a2472385&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4526","BK4588","BK4548","ZLAB","BK4531","09688"],"gpt_icon":0},{"id":"2484318125","title":"再鼎医药根据包销协议发行1176.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484318125","media":"新浪港股","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484318125?lang=zh_cn&edition=full","pubTime":"2024-11-20 09:07","pubTimestamp":1732064857,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)发布公告,根据包销协议,就发售于2024年11月19日(美国东部时间)在期权获包销商悉数行使后配发及发行新股份作为期权美国存托股份的相关股份1176.47万股。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-20/doc-incwsiqw2302330.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-20/doc-incwsiqw2302330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1574","BK1588","09688","BK1161"],"gpt_icon":0},{"id":"2484869561","title":"再鼎医药(09688)根据包销协议发行1176.47万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484869561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484869561?lang=zh_cn&edition=full","pubTime":"2024-11-20 08:25","pubTimestamp":1732062331,"startTime":"0","endTime":"0","summary":"智通财经APP讯,再鼎医药(09688)发布公告,根据包销协议,就发售于2024年11月19日(美国东部时间)在期权获包销商悉数行使后配发及发行新股份作为期权美国存托股份的相关股份1176.47万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4139","BK4526","09688","BK4548","BK1161","ZLAB","BK1588","BK4588","BK4585","BK1574"],"gpt_icon":0},{"id":"2484212319","title":"再鼎医药上涨5.16%,报26.47美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484212319","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484212319?lang=zh_cn&edition=full","pubTime":"2024-11-19 23:51","pubTimestamp":1732031491,"startTime":"0","endTime":"0","summary":"11月19日,再鼎医药(ZLAB)盘中上涨5.16%,截至23:51,报26.47美元/股,成交590.52万美元。财务数据显示,截至2024年09月30日,再鼎医药收入总额2.9亿美元,同比增长44.32%;归母净利润-1.75亿美元,同比增长26.66%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/19235145470667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4548","09688","ZLAB","BK1588","BK4139","BK1161","BK4585","BK4588","BK4526","BK1574","BK4531"],"gpt_icon":0},{"id":"2484942252","title":"再鼎医药(ZLAB)盘前涨超2% 获威灵顿投资管理增持1,012.5万股H股股份 价值约2.82亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484942252","media":"金吾财讯","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484942252?lang=zh_cn&edition=full","pubTime":"2024-11-19 21:42","pubTimestamp":1732023775,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(ZLAB)盘前涨超2%,截至发稿,报25.8美元。消息面上,根据香港联交所11月19日披露的文件,威灵顿投资管理(Wellington Management Group LLP)于11月15日以每股均价27.803美元增持再鼎医药1,012.5万股H股股份,价值约2.82亿美元。增持后,威灵顿投资管理最新持股数目为1.01亿股股份,持仓比例由9.14%升至10.15%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/ZjE4MDdhNTRkYTVhY2QzODgyOWQwYzcxZDQ3NTA3Njg3NjgwMzk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZjE4MDdhNTRkYTVhY2QzODgyOWQwYzcxZDQ3NTA3Njg3NjgwMzk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282173","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4139","BK4548","BK4531","BK1588","BK4526","BK4585","BK1161","ZLAB","09688","BK4588"],"gpt_icon":0},{"id":"2484915360","title":"再鼎医药(09688)授出1.5万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2484915360","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484915360?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:10","pubTimestamp":1732011020,"startTime":"0","endTime":"0","summary":"智通财经APP讯,再鼎医药(09688)发布公告,于授出日期,公司根据2024年股权激励计划条款向8名承授人授出1.5万份受限制股份单位(以美国存托股份计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","ZLAB","BK4548","BK1574","BK1588","BK4526","BK4139","BK4588","BK1161","BK4585","BK4531"],"gpt_icon":0},{"id":"2484999501","title":"再鼎医药11月19日收跌4.48% 主力资金逆市抢筹","url":"https://stock-news.laohu8.com/highlight/detail?id=2484999501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484999501?lang=zh_cn&edition=full","pubTime":"2024-11-19 16:15","pubTimestamp":1732004152,"startTime":"0","endTime":"0","summary":"11月19日, 再鼎医药股价跌4.48%,报收20.25元,成交金额2.04亿元,换手率0.94%,振幅3.30%,量比1.65。再鼎医药今日主力资金净流入4437万元,连续5日净流入,上一交易日主力净流入2570万元,今日环比增加72.65%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为41.67%,平均涨幅为4.55%。该股近5个交易日下跌17.18%,主力资金累计净流入1.75亿元;近20日主力资金累计净流入1.98亿元,其中净流入天数为15日。该股主力净额占比0.20%,港股市场排名18/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119161615abcea145&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119161615abcea145&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09688","BK1574","BK1588"],"gpt_icon":0},{"id":"2484955906","title":"深度 | 再鼎医药融资上瘾,累计亏损超20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955906","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484955906?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:03","pubTimestamp":1731981780,"startTime":"0","endTime":"0","summary":"11月15日,再鼎医药发布公告,计划发售784万股美国存托股份,代表7843万股相关股份,发售价为每股25.5美元。公告指出,此次发售所得款项预计在2亿美元至2.3亿美元,净额预计在1.88亿美元至2.16亿美元。据《财中社》不完全统计,包括本次发行美国存托股份在内,再鼎医药累计融资金额达到13.3亿美元,换算成人民币95.8亿元。然而,公司还没有盈利过,2015年至今累计亏损额达到23.66亿美元,换算成人民币171.4亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119100751a24465e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119100751a24465e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","09688","BK4588","BK4585","BK4531","BK4139","BK4548","ZLAB"],"gpt_icon":0},{"id":"1147528400","title":"异动解读 | 再鼎医药盘中大跌6.7% 新股发行致股权稀释","url":"https://stock-news.laohu8.com/highlight/detail?id=1147528400","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147528400?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:39","pubTimestamp":1731980356,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)今日盘中股价大跌6.7%,引发市场广泛关注。\n公司方面,再鼎医药近期根据包销协议发行了7843.14万股新股,导致现有股东所持股权遭到稀释。增发新股通常会对股价产生一定压力,这或许是再鼎医药今日股价大跌的主要原因之一。\n不过,股权稀释只是导致再鼎医药股价下跌可能原因之一,其他潜在因素如基本面变化、市场情绪等也不容忽视。股价下跌的具体原因仍有待后续观察和分析。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 再鼎医药盘中大跌6.7% 新股发行致股权稀释","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09688"],"gpt_icon":0},{"id":"2484583039","title":"再鼎医药盘中异动 大幅跳水6.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484583039","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484583039?lang=zh_cn&edition=full","pubTime":"2024-11-19 09:32","pubTimestamp":1731979922,"startTime":"0","endTime":"0","summary":"2024年11月19日早盘09时32分,再鼎医药股票出现波动,股价急速下跌6.13%。截至发稿,该股报19.900港元/股,成交量42.66万股,换手率0.04%,振幅0.94%。再鼎医药股票所在的生物技术行业中,整体跌幅为0.35%。其相关个股中,云顶新耀-B、科济药业-B、乐普生物-B涨幅较大,振幅较大的相关个股有荣昌生物、贝康医疗-B、云顶新耀-B,振幅分别为5.78%、5.42%、4.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093202971a74d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119093202971a74d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1161","09688","BK1574"],"gpt_icon":0},{"id":"2484934002","title":"再鼎医药根据包销协议发行7843.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484934002","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484934002?lang=zh_cn&edition=full","pubTime":"2024-11-19 08:42","pubTimestamp":1731976920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 再鼎医药(09688)发布公告,根据包销协议,就发售于2024年11月18日(美国东部时间)配发及发行新股份作为包销美国存托股份的相关股份7843.14万股。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-19/doc-incwpyiw6348530.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-19/doc-incwpyiw6348530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4585","BK1161","ZLAB","BK1574","BK4526","BK1588","BK4588","BK4548","BK4531","09688"],"gpt_icon":0},{"id":"2484392249","title":"再鼎医药(09688)根据包销协议发行7843.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484392249","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484392249?lang=zh_cn&edition=full","pubTime":"2024-11-19 08:05","pubTimestamp":1731974723,"startTime":"0","endTime":"0","summary":"智通财经APP讯,再鼎医药(09688)发布公告,根据包销协议,就发售于2024年11月18日(美国东部时间)配发及发行新股份作为包销美国存托股份的相关股份7843.14万股。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4531","BK4139","BK4585","BK4588","ZLAB","BK1161","BK1574","BK1588","BK4548","09688","BK4526"],"gpt_icon":0},{"id":"2483372909","title":"再鼎医药盘中异动 股价大涨8.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483372909","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483372909?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:31","pubTimestamp":1731681071,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日22时31分,再鼎医药股票出现波动,股价大幅拉升8.44%。截至发稿,该股报28.92美元/股,成交量40.2947万股,换手率0.41%,振幅0.37%。再鼎医药股票所在的生物技术行业中,整体跌幅为0.69%。该信息摘要如下:创新药企再鼎医药持续减亏。11月12日晚间,再鼎医药发布三季报,财报显示,今年第三季度公司产品收入净额为1.018亿美元,2023年同期为6920万美元,同比增长47%。在港上市以来,再鼎医药的营收规模快速增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111522311195be33f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111522311195be33f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4588","BK4585","09688","BK4531","BK4139","BK4526","BK4548"],"gpt_icon":0},{"id":"2483841324","title":"摩根大通增持再鼎医药(09688)118.31万股 每股作价约24.56港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483841324","media":"智通财经网","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483841324?lang=zh_cn&edition=full","pubTime":"2024-11-15 19:11","pubTimestamp":1731669060,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示,11月11日,摩根大通增持再鼎医药(09688)118.31万股,每股作价24.5597港元,总金额约为2905.66万港元。增持后最新持股数目约为1.40亿股,最新持股比例为14.01%。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-15/doc-incwczme6195600.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-15/doc-incwczme6195600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B1XK9C88.USD","LU0417517546.SGD","IE00BKVL7J92.USD","LU0787776722.HKD","LU1119994496.HKD","LU0215105999.USD","IE00BLSP4239.USD","LU0976567544.SGD","LU2552382215.SGD","LU0320765489.SGD","LU1032466523.USD","LU1084165304.USD","BK1161","IE000M9KFDE8.USD","LU1244550577.SGD","LU1670627923.USD","LU1988902786.USD","IE00BDCRKT87.USD","LU2237443549.SGD","ZLAB","IE00BFXG1179.USD","LU2106854487.HKD","LU1261432733.SGD","LU1894683264.USD","LU0211327993.USD","LU2023250504.SGD","LU2264538146.SGD","IE00B3S45H60.SGD","LU1894683348.USD","IE0034235188.USD","IE00BHPRN162.USD","BK4139","LU0203347892.USD","IE0034235295.USD","LU1496350171.SGD","LU2237443382.USD","BK4566","LU0267386448.USD","IE00B1BXHZ80.USD","09688","LU0234572021.USD","LU0238689110.USD","BK4533","IE00BLSP4452.SGD","LU1363072403.SGD","IE00BJTD4N35.SGD","IE00BYXW3230.USD","LU1244550494.USD","BK4581","LU0683600562.USD"],"gpt_icon":0},{"id":"2483334444","title":"再鼎医药盘前涨2.4% 配售美国存托股份 净筹不超2.16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483334444","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483334444?lang=zh_cn&edition=full","pubTime":"2024-11-15 17:18","pubTimestamp":1731662280,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)盘前涨2.4%报27.31美元。消息上,公司拟配售合共784.31万股美国存托股份,相当于扩大后普通股约8.3%,每股作价25.5美元(相当于每股19.84港元)。集团预期净集资介乎1.88亿至2.16亿美元(约14.61亿至16.82亿港元),拟用于一般企业用途。此外,浦银国际发表报告指,再鼎医药第三季净亏损显著收窄,好于预期。(格隆汇)\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:郭明煜","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-11-15/doc-incwcvch6275190.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-11-15/doc-incwcvch6275190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK4526","09688","BK4588","BK1161","BK4531","BK4139","BK4548","BK1588","ZLAB","BK4585"],"gpt_icon":0},{"id":"2483362107","title":"再鼎医药(09688.HK)折让逾4%配售美国存托股份 净筹最多2.16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483362107","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483362107?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:49","pubTimestamp":1731635340,"startTime":"0","endTime":"0","summary":"再鼎医药(09688.HK) (ZLAB.US) 公布,拟配售合共784.31万股美国存托股份,相当于扩大后普通股约8.3%,每股作价25.5美元(相当于每股19.84港元),较周四(14日)收市价26.67美元折让约4.39%。集团预期净集资介乎1.88亿至2.16亿美元(约14.61亿至16.82亿港元),拟用于一般企业用途。(jl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-14 16:25。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200925164731789_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200925164731789_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396896/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1588","BK1161","09688"],"gpt_icon":0},{"id":"2483836193","title":"再鼎医药::第三季度总产品净收入同比增长47%,经营性亏损收窄19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483836193","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483836193?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:35","pubTimestamp":1731634545,"startTime":"0","endTime":"0","summary":"来源:Gangtise投研\n再鼎医药(ZLAB.US/09688.HK) 2024年第三季度业绩电话会:第三季度总产品净收入同比增长47%,经营性亏损收窄19%,净亏损减少40%,业绩亮眼。爱加默德单季度销售额达2730万美元,市场覆盖约65%,近2000名医生开过处方,重复处方比例近40%,累计近1万名患者接受治疗。公司未来发展战略聚焦营收增长、全球管线扩充和运营效率提升,计划2024年底前递交至少4个上市申请。其他管线产品如1310、阿尔赛文电影等也在积极推进中。公司对2025年销售峰值和市场潜力持乐观态度。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/relnews/us/2024-11-15/doc-incwcefq6444993.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/us/2024-11-15/doc-incwcefq6444993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1588","BK1574","BK1161","09688"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0766},{"period":"1month","weight":-0.0487},{"period":"3month","weight":0.4791},{"period":"6month","weight":0.4477},{"period":"1year","weight":-0.0421},{"period":"ytd","weight":-0.0465}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0438},{"period":"3month","weight":0.1129},{"period":"6month","weight":0.0533},{"period":"1year","weight":0.1052},{"period":"ytd","weight":0.1498}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法,以解决中国市场中大量未满足医疗需求的领域,包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib(ZL-2306)、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.016509},{"month":2,"riseRate":0.5,"avgChangeRate":-0.001648},{"month":3,"riseRate":0,"avgChangeRate":-0.143693},{"month":4,"riseRate":0.75,"avgChangeRate":0.076104},{"month":5,"riseRate":0.5,"avgChangeRate":-0.025575},{"month":6,"riseRate":0.25,"avgChangeRate":-0.052584},{"month":7,"riseRate":0.75,"avgChangeRate":0.064885},{"month":8,"riseRate":0.75,"avgChangeRate":0.004625},{"month":9,"riseRate":0.25,"avgChangeRate":-0.078066},{"month":10,"riseRate":0.6,"avgChangeRate":-0.01228},{"month":11,"riseRate":0.6,"avgChangeRate":0.08297},{"month":12,"riseRate":0.5,"avgChangeRate":0.014831}],"exchange":"SEHK","name":"再鼎医药","nameEN":"ZAI LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,09688,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(09688)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(09688)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}